Pharmacogenomics in the age of personalized medicine

Leslie J Dickmann; Joseph A Ware

doi:10.1016/j.ddtec.2016.11.003

Pharmacogenomics in the age of personalized medicine

Drug Discov Today Technol. 2016 Sep-Dec:21-22:11-16. doi: 10.1016/j.ddtec.2016.11.003.

Authors

Leslie J Dickmann¹, Joseph A Ware²

Affiliations

¹ Department of Clinical Pharmacology, Genentech, 1 DNA Way, South San Francisco, CA 94080, United States. Electronic address: dickmanl@gene.com.
² Department of Clinical Pharmacology, Genentech, 1 DNA Way, South San Francisco, CA 94080, United States.

PMID: 27978982
DOI: 10.1016/j.ddtec.2016.11.003

Abstract

The aim of personalized medicine is to offer the right treatment to the right person at the right dose, thus maximizing efficacy and minimizing toxicity for each individual patient. Pharmacogenomic approaches attempt to refine the aim of personalized medicine by utilizing an individual's germline and somatic DNA signatures to guide treatment. In this review, we highlight the current use of pharmacogenomic based biomarker information in drug labeling. We also present several case studies on the implementation of pharmacogenomic strategies in drug discovery and development. Lastly, we comment on current challenges to implementing pharmacogenomic based testing in the clinic.

Publication types

Review

MeSH terms

Drug Discovery
Drug Labeling
Humans
Neoplasms / drug therapy
Neoplasms / genetics
Pharmacogenetics*
Precision Medicine*